OncoResponse announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The CPRIT award and investment will support the advancement of OR502, a best-in-class anti-LILRB2 antibody poised to move to investigational new drug and clinical studies.
[OncoResponse]